Clinical Trial Update: Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update discusses the use of Taxotere (docetaxel) as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma, spa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Head and Neck Neoplasms, Neoplasm Recurrence, Local | Phase 2, Phase 3 | Status: COMPLETED